Supreme Court Appears Dubious Of Gene Patents, But Wary Of Halting Innovation
This article was originally published in The Gray Sheet
Executive Summary
Justices appeared to favor the government’s position that synthesized genetic material, but not isolated DNA, can be eligible for a patent during oral arguments last week in the case of The Association of Molecular Pathology v. Myriad Genetics Inc.
You may also be interested in...
Diagnostic Companies Rush To Test Formerly Off-Limit Genes
Although Myriad says the Supreme Court’s recent ruling that isolated genes can’t be patented does not leave its BRCA1 and BRCA2 assays unprotected, other diagnostic companies are now incorporating the genes into their tests for the likelihood of inheriting cancer at a fraction of the previous cost.
Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout
Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can be.
News In Brief
Tavenner confirmed as CMS chief. DePuy phases out metal hips. More news